Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models

European Journal of Pharmacology

Volumn 669, Issue 1-3, 2011, Pages 84-93

  Kusumoto, Keiji ^a   Igata, Hideki ^a   Ojima, Mami ^a   Tsuboi, Ayako ^a   Imanishi, Mitsuaki ^a   Yamaguchi, Fuminari ^a   Sakamoto, Hiroki ^a   Kuroita, Takanobu ^a   Kawaguchi, Naohiro ^a   Nishigaki, Nobuhiro ^a   Nagaya, Hideaki ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Angiotensin II type 1 receptor; Azilsartan medoxomil; Hypertension; Insulin resistance; Proteinuria; TAK 491

Indexed keywords

AZILSARTAN MEDOXOMIL; INSULIN; OLMESARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DOG; DRUG DETERMINATION; DRUG EFFECT; DRUG INHIBITION; DRUG STRUCTURE; GLUCOSE INFUSION; HYPERTENSION; INSULIN SENSITIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; TREATMENT RESPONSE;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD GLUCOSE; BLOOD PRESSURE; CHO CELLS; CRICETINAE; CRICETULUS; DOGS; HYPERTENSION; HYPERTENSION, RENAL; IMIDAZOLES; INSULIN; MALE; OXADIAZOLES; PROTECTIVE AGENTS; PROTEINURIA; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; TETRAZOLES;

EID: 80053306578     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.07.014     Document Type: Article

References (40)

1. V. Agrawal, V. Marinescu, M. Agarwal, and P.A. McCullough Cardiovascular implications of proteinuria: an indicator of chronic kidney disease Nat. Rev. Cardiol. 6 2009 301 311
2. B.M. Brenner, M.E. Cooper, D. de Zeeuw, W.F. Keane, W.E. Mitch, H.H. Parving, G. Remuzzi, S.M. Snapinn, Z. Zhang, and S. Shahinfar Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N. Engl. J. Med. 345 2001 861 869
3. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, A.G. Green, A.L. Izzo, D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright, and E.J. Roccella The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JAMA 289 2003 2560 2572 (Pubitemid 37430158)
4. S.E. Easthope, and B. Jarvis Candesartan cilexetil: an update of its use in essential hypertension Drugs 62 2002 1253 1287 (Pubitemid 34591101)
5. W.J. Elliott Management of hypertension in the very elderly patient Hypertension 44 2004 800 804 (Pubitemid 39577400)
6. C. Ferrario, A.I. Abdelhamed, and M. Moore All antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan Curr. Med. Res. Opin. 20 2004 279 293 (Pubitemid 38339169)
7. F.L. Fierens, P.M. Vanderheyden, Z. Gáborik, T.L. Minh, J.P. Backer, L. Hunyady, A. Ijzerman, and G. Vauquelin Lys(199) mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists J. Renin Angiotensin Aldosterone Syst. 1 2000 283 288
8. G.J. Fodor, M. Kotrec, K. Bacskai, T. Dorner, J. Lietava, S. Sonkodi, A. Rieder, and P. Turton Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central-European study J. Hypertens. 23 2005 1261 1266 (Pubitemid 40862731)
9. M. Furuhashi, N. Ura, H. Murakami, M. Hyakukoku, K. Yamaguchi, K. Higashiura, and K. Shimamoto Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and β-oxidation in skeletal muscle J. Endocrinol. 174 2002 321 329 (Pubitemid 34965771)
10. W.F. Graettinger Systemic hypertension M.H. Crawford, Current Diagnosis & Treatment in Cardiology 2nd ed. 2003 173 175 New York, NY
11. S.M. Haffner, M.P. Stern, H.P. Hazuda, B.D. Mitchell, and J.K. Patterson Cardiovascular risk factors in confirmed prediabetic individuals J. Am. Med. Assoc. 263 1990 2893 2898 (Pubitemid 20173164)
12. G. Howard, D.H. O'Leary, D. Zaccaro, S. Haffner, M. Rewers, R. Hamman, J.V. Selby, M.F. Saad, P. Savage, and R. Bergman Insulin sensitivity and atherosclerosis Circulation 93 1996 1809 1817 (Pubitemid 26154032)
13. O. Iimura, K. Shimamoto, K. Matsuda, A. Masuda, H. Takizawa, K. Higashiura, Y. Miyazaki, A. Hirata, N. Ura, and M. Nakagawa Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives Am. J. Hypertens. 8 1995 353 357
14. Y. Inada, T. Wada, Y. Shibouta, M. Ojima, T. Sanada, K. Ohtsuki, K. Itoh, K. Kubo, Y. Kohara, T. Naka, and K. Nishikawa Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (±)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol- 5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats J. Pharmacol. Exp. Ther. 268 1994 1540 1554
15. M. Iwai, R. Chen, Y. Imura, and M. Horiuchi Azilsartan, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation Am. J. Hypertens. 20 2007 579 586 (Pubitemid 46678714)
16. J.A. Jefferson, S.J. Shankland, and R.H. Pichler Proteinuria in diabetic kidney disease: a mechanistic viewpoint Kidney Int. 74 2008 22 36 (Pubitemid 351841893)
17. K. Kario Blood pressure variability in hypertension: a possible cardiovascular risk factor Am. J. Hypertens. 17 2004 1075 1076 (Pubitemid 39469333)
18. P.M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P.K. Whelton, and J. He Global burden of hypertension: analysis of worldwide data Lancet 365 2005 217 223 (Pubitemid 40138015)
19. K. Kusumoto, Y. Awane, T. Kitayoshi, S. Fujiwara, S. Hashiguchi, Z. Terashita, M. Shiraishi, and T. Watanabe Antihypertensive and cardiovascular effects of a new potassium channel opener, TCV-295, in rats and dogs J. Cardiovasc. Pharmacol. 24 1994 929 936
20. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis, E. Ritz, R.C. Atkins, R. Rohde, and I. Raz Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N. Engl. J. Med. 345 2001 851 860
21. G. Mancia Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study Circulation 111 2005 1777 1783 (Pubitemid 40525142)
22. G. Mancia Blood pressure reduction and cardiovascular outcomes: past, present, and future Am. J. Cardiol. 100 2007 3J 9J
23. G. Mancia, R. Facchetti, M. Bombelli, G. Grassi, and R. Sega Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure Hypertension 47 2006 846 853 (Pubitemid 44297554)
24. G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A.M. Heagerty, S.E. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R.E. Schmieder, H.A. Boudier, and A. Zanchetti 2007 ESH-ESC practice guidelines for the management of arterial hypertension J. Hypertens. 25 2007 1751 1762
25. M. Mizuno, T. Sada, M. Kato, Y. Fukushima, H. Terashima, and H. Koike The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes J. Cardiovasc. Pharmacol. 48 2006 135 142 (Pubitemid 44691214)
26. H. Mori, H. Ukai, H. Yamamoto, S. Saitou, K. Hirao, M. Yamauchi, and S. Umemura Current status of antihypertensive prescription and associated blood pressure control in Japan Hypertens. Res. 29 2006 143 151
27. D. Murdoch, and R.N. Brogden Sustained release nifedipine formulations Drugs 41 1991 737 779
28. M. Noda, Y. Shibouta, Y. Inada, M. Ojima, T. Wada, T. Sanada, K. Kubo, Y. Kohara, T. Naka, and K. Nishikawa Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist Biochem. Pharmacol. 46 1993 311 318 (Pubitemid 23218618)
29. M. Noda, T. Matsuo, H. Nagano-Tsuge, M. Ohta, M. Sekiguchi, Y. Shibouta, T. Naka, and Y. Imura Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats) Jpn. J. Pharmacol. 85 2001 416 422
30. T. Ogihara, K. Kikuchi, H. Matsuoka, T. Fujita, J. Higaki, M. Horiuchi, Y. Imai, T. Imaizumi, S. Ito, H. Iwao, K. Kario, Y. Kawano, S. Kim-Mitsuyama, G. Kimura, H. Matsubara, H. Matsuura, M. Naruse, I. Saito, K. Shimada, K. Shimamoto, H. Suzuki, S. Takishita, N. Tanahashi, T. Tsuchihashi, M. Uchiyama, S. Ueda, H. Ueshima, S. Umemura, T. Ishimitsu, and H. Rakugi The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) Hypertens. Res. 32 2009 3 107
31. M. Ojima, Y. Inada, Y. Shibouta, T. Wada, T. Sanada, K. Kubo, and K. Nishikawa Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor Eur. J. Pharmacol. 319 1997 137 146 (Pubitemid 27051327)
32. M. Ojima, H. Igata, M. Tanaka, H. Sakamoto, T. Kuroita, Y. Kohara, K. Kubo, H. Fuse, Y. Imura, K. Kusumoto, and H. Nagaya In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies J. Pharmacol. Exp. Ther. 336 2011 801 808
33. H.H. Parving, H. Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Andersen, and P. Arner The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N. Engl. J. Med. 345 2001 870 878
34. P. Ruggenenti, A. Schieppati, and G. Remuzzi Progression, remission, regression of chronic renal disease Lancet 357 2001 1601 1608 (Pubitemid 32488830)
35. Y. Shibouta, Y. Inada, M. Ojima, T. Wada, M. Noda, T. Sanada, K. Kubo, Y. Kohara, T. Naka, and K. Nishikawa Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H- tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl]-1H-benzimidazole- 7-carboxylate (TCV-116) J. Pharmacol. Exp. Ther. 266 1993 114 120
36. K.O. Stumpe Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials Clin. Ther. 26 Suppl A 2004 A33 A37
37. R.S. Vasan, A. Beiser, S. Seshadri, M.G. Larson, W.B. Kannel, R.B. D'Agostino, and D. Levy Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study JAMA 287 2002 1003 1010 (Pubitemid 34252058)
38. M.A. Weber The angiotensin II receptor blockers: opportunities across the spectrum of cardiovascular disease Rev. Cardiovasc. Med. 3 2002 183 191 (Pubitemid 36013538)
39. M.R. Weir, E.W. Maibach, G.L. Bakris, H.R. Black, P. Chawla, F.H. Messerli, J.M. Neutel, and M.A. Weber Implications of a healthy lifestyle and medication analysis for improving hypertension control Arch. Intern. Med. 160 2000 481 490 (Pubitemid 30112271)
40. W.B. White, M.A. Weber, D. Sica, G.L. Bakris, A. Perez, C. Cao, and S. Kupfer Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension Hypertension 57 2011 413 420